|
| Status |
Public on Jan 01, 2018 |
| Title |
Human A375 melanoma cell line treated with trifluorothymidine (TFT) and lactimidomycin (LTM) |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
To generate drug signatures in human A375 melanoma cell lines. A375 cell line was plated at 4 x 105 cells/mL overnight and treated with trifluridine or lactimidomycin at 75% inhibitory concentrations (IC75, determined previously at 72h of treatment) or DMSO (vehicle) for 8h or 24h before harvest.
|
| |
|
| Overall design |
To find out whether drug signatures generated in human melanoma cell lines are predictive of outcome in melanoma patients, we generated trifluorothymidine(TFT) and lactimidomycin(LTM) signatures in cell lines A375 . The expression of drug signatures were then tested by using GSSA (Gene Signature Survival Analysis) method to find out correlation with clinical outcome of melanoma patients.
|
| |
|
| Contributor(s) |
Ma W, Du L, Wang Z, Davis RE, Tsai KY |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Jul 08, 2014 |
| Last update date |
Aug 13, 2018 |
| Contact name |
Wencai Ma |
| Organization name |
MD Anderson Cancer Center
|
| Street address |
7455 Fannin st
|
| City |
Houston |
| ZIP/Postal code |
77054 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL10558 |
Illumina HumanHT-12 V4.0 expression beadchip |
|
| Samples (12)
|
|
| This SubSeries is part of SuperSeries: |
| GSE59409 |
Correlating Gene Signatures with Outcome to find Features and Drugs Relevant to Cancer |
|
| Relations |
| BioProject |
PRJNA254572 |
Less...
More...